CANbridge Pharmaceuticals Reshuffles Corporate Secretariat: Mr. Wai Chiu Wong to Depart, Ms. Qian Ma and Ms. Lin Sio Ngo Assume Key Roles

Bulletin Express03-31 06:25

CANbridge Pharmaceuticals Inc. (CANbridge) has announced forthcoming changes to its corporate secretariat and compliance structure, effective 30 March 2026.

Mr. Wai Chiu Wong will step down as Joint Company Secretary, cease to serve as an Authorised Representative under Rule 3.05 of the Hong Kong Listing Rules, and relinquish his position as the company’s Process Agent under Part 16 of the Companies Ordinance. Mr. Wong confirmed he has no disagreement with the Board and is unaware of any matters that should be brought to shareholders’ attention.

Following his departure: • Ms. Qian Ma, the remaining Joint Company Secretary who meets the qualifications under Listing Rules 3.28 and 8.17, will continue as Company Secretary and concurrently take up the role of Authorised Representative. • Ms. Lin Sio Ngo has been appointed as the new Process Agent.

The Board expressed appreciation for Mr. Wong’s contributions and extended its welcome to Ms. Ma and Ms. Lin in their new capacities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108289227?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108289227","market":"hk","top_or_hot":-1,"title":"CANbridge Pharmaceuticals Reshuffles Corporate Secretariat: Mr. Wai Chiu Wong to Depart, Ms. Qian Ma and Ms. Lin Sio Ngo Assume Key Roles","media":"Bulletin Express","content":"<p>CANbridge Pharmaceuticals Inc. (CANbridge) has announced forthcoming changes to its corporate secretariat and compliance structure, effective 30 March 2026.</p>\n<p>Mr. Wai Chiu Wong will step down as Joint Company Secretary, cease to serve as an Authorised Representative under Rule 3.05 of the Hong Kong Listing Rules, and relinquish his position as the company’s Process Agent under Part 16 of the Companies Ordinance. Mr. Wong confirmed he has no disagreement with the Board and is unaware of any matters that should be brought to shareholders’ attention.</p>\n<p>Following his departure:  \n• Ms. Qian Ma, the remaining Joint Company Secretary who meets the qualifications under Listing Rules 3.28 and 8.17, will continue as Company Secretary and concurrently take up the role of Authorised Representative.  \n• Ms. Lin Sio Ngo has been appointed as the new Process Agent.</p>\n<p>The Board expressed appreciation for Mr. Wong’s contributions and extended its welcome to Ms. Ma and Ms. Lin in their new capacities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANbridge Pharmaceuticals Reshuffles Corporate Secretariat: Mr. Wai Chiu Wong to Depart, Ms. Qian Ma and Ms. Lin Sio Ngo Assume Key Roles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANbridge Pharmaceuticals Reshuffles Corporate Secretariat: Mr. Wai Chiu Wong to Depart, Ms. Qian Ma and Ms. Lin Sio Ngo Assume Key Roles\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-31 06:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANbridge Pharmaceuticals Inc. (CANbridge) has announced forthcoming changes to its corporate secretariat and compliance structure, effective 30 March 2026.</p>\n<p>Mr. Wai Chiu Wong will step down as Joint Company Secretary, cease to serve as an Authorised Representative under Rule 3.05 of the Hong Kong Listing Rules, and relinquish his position as the company’s Process Agent under Part 16 of the Companies Ordinance. Mr. Wong confirmed he has no disagreement with the Board and is unaware of any matters that should be brought to shareholders’ attention.</p>\n<p>Following his departure:  \n• Ms. Qian Ma, the remaining Joint Company Secretary who meets the qualifications under Listing Rules 3.28 and 8.17, will continue as Company Secretary and concurrently take up the role of Authorised Representative.  \n• Ms. Lin Sio Ngo has been appointed as the new Process Agent.</p>\n<p>The Board expressed appreciation for Mr. Wong’s contributions and extended its welcome to Ms. Ma and Ms. Lin in their new capacities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01228","symbol_name":"北海康成-B","start_time":0,"source_url":"","article_id":"1108289227","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108289227","pubTimestamp":1774909559,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CANbridge Pharmaceuticals Inc. (CANbridge) has announced forthcoming changes to its corporate secretariat and compliance structure, effective 30 March 2026. Mr. Wai Chiu Wong will step down as Joint...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01228":"北海康成-B"},"translate_title":"CANbridge Pharmaceuticals改组公司秘书处：Wai Chiu Wong先生离职，Qian Ma女士和Lin Sio Ngo女士担任关键角色","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01228":1},"content_text":"CANbridge Pharmaceuticals Inc. (CANbridge) has announced forthcoming changes to its corporate secretariat and compliance structure, effective 30 March 2026.\nMr. Wai Chiu Wong will step down as Joint Company Secretary, cease to serve as an Authorised Representative under Rule 3.05 of the Hong Kong Listing Rules, and relinquish his position as the company’s Process Agent under Part 16 of the Companies Ordinance. Mr. Wong confirmed he has no disagreement with the Board and is unaware of any matters that should be brought to shareholders’ attention.\nFollowing his departure:  \n• Ms. Qian Ma, the remaining Joint Company Secretary who meets the qualifications under Listing Rules 3.28 and 8.17, will continue as Company Secretary and concurrently take up the role of Authorised Representative.  \n• Ms. Lin Sio Ngo has been appointed as the new Process Agent.\nThe Board expressed appreciation for Mr. Wong’s contributions and extended its welcome to Ms. Ma and Ms. Lin in their new capacities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108289227","isCrawlerRequest":true}